These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27527259)

  • 1. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.
    Beaudoin J; Singh JP; Szymonifka J; Zhou Q; Levine RA; Januzzi JL; Truong QA
    Can J Cardiol; 2016 Dec; 32(12):1478-1484. PubMed ID: 27527259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.
    Truong QA; Januzzi JL; Szymonifka J; Thai WE; Wai B; Lavender Z; Sharma U; Sandoval RM; Grunau ZS; Basnet S; Babatunde A; Ajijola OA; Min JK; Singh JP
    Heart Rhythm; 2014 Dec; 11(12):2167-75. PubMed ID: 25014756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 and ST2 as predictors of therapeutic success in high-risk patients undergoing percutaneous mitral valve repair (MitraClip).
    Dörr O; Walther C; Liebetrau C; Keller T; Sommer T; Boeder N; Bayer M; Bauer P; Möllmann H; Gaede L; Troidl C; Voss S; Bauer T; Hamm CW; Nef H
    Clin Cardiol; 2018 Sep; 41(9):1164-1169. PubMed ID: 29896861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midregional-proAtrial Natriuretic Peptide and High Sensitive Troponin T Strongly Predict Adverse Outcome in Patients Undergoing Percutaneous Repair of Mitral Valve Regurgitation.
    Wöhrle J; Karakas M; Trepte U; Seeger J; Gonska B; Koenig W; Rottbauer W
    PLoS One; 2015; 10(9):e0137464. PubMed ID: 26368980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers.
    Sunman H; Özkan A; Yorgun H; Canpolat U; Karabulut E; Bayrak T; Kaya EB; Tokgözoğlu L; Özer N; Özkara A; Aytemir K; Oto A
    Cardiol J; 2018; 25(1):42-51. PubMed ID: 28980281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.
    Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP
    Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
    Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
    Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 receptor-related protein ST2 and mitral valve repair outcome in patients with chronic degenerative mitral regurgitation.
    Galeone A; Lessana A; Mascolo E; Di Serio F; Marraudino N; Laborde F; Paparella D
    Thorac Cardiovasc Surg; 2014 Feb; 62(1):47-51. PubMed ID: 24065602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive hemodynamics and cardiac biomarkers to predict outcomes after percutaneous edge-to-edge mitral valve repair in patients with severe heart failure.
    Kreusser MM; Geis NA; Berlin N; Greiner S; Pleger ST; Bekeredjian R; Katus HA; Raake PW
    Clin Res Cardiol; 2019 Apr; 108(4):375-387. PubMed ID: 30191296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cardiac resynchronization therapy on mitral valve apparatus geometry and clinical outcomes in patients with secondary mitral regurgitation.
    Mihos CG; Yucel E; Capoulade R; Orencole MP; Upadhyay GA; Santana O; Singh JP; Picard MH
    Echocardiography; 2017 Nov; 34(11):1561-1567. PubMed ID: 28895197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk.
    van Bommel RJ; Marsan NA; Delgado V; Borleffs CJ; van Rijnsoever EP; Schalij MJ; Bax JJ
    Circulation; 2011 Aug; 124(8):912-9. PubMed ID: 21810666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-based risk prediction in the community.
    AbouEzzeddine OF; McKie PM; Scott CG; Rodeheffer RJ; Chen HH; Michael Felker G; Jaffe AS; Burnett JC; Redfield MM
    Eur J Heart Fail; 2016 Nov; 18(11):1342-1350. PubMed ID: 27813304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.
    Skali H; Gerwien R; Meyer TE; Snider JV; Solomon SD; Stolen CM
    J Cardiovasc Transl Res; 2016 Dec; 9(5-6):421-428. PubMed ID: 27798759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation.
    Potocki M; Mair J; Weber M; Hamm C; Burkard T; Hiemetzberger R; Peters K; Jander N; Cron TA; Hess N; Hoffmann A; Gekeler H; Gohlke-Bärwolf C; Buser P; Mueller C
    Am J Cardiol; 2009 Aug; 104(4):559-64. PubMed ID: 19660612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Mitral Valve Pressure Gradient After MitraClip Implantation Deteriorates Long-Term Outcome in Patients With Severe Mitral Regurgitation and Severe Heart Failure.
    Neuss M; Schau T; Isotani A; Pilz M; Schöpp M; Butter C
    JACC Cardiovasc Interv; 2017 May; 10(9):931-939. PubMed ID: 28473116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.